Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first ‐line platinum chemotherapy in high grade serous ovarian cancer

ConclusionsOur research demonstrates that tumors from HGSOC patients responding poorly to first line chemotherapy have a distinct molecular profile characterized by actionable drug targets including PARP4.

Source: Cancer Medicine - April 3, 2021 Category: Cancer & Oncology Authors: Johanne I. Weberpals, Trevor J. Pugh, Paola Marco ‐Casanova, Glenwood D. Goss, Natalie Andrews Wright, Prisni Rath, Jonathon Torchia, Alexander Fortuna, Gemma N. Jones, Martine P. Roudier, Laurence Bernard, Bryan Lo, Dax Torti, Alberto Leon Tags: ORIGINAL RESEARCH Source Type: research